Premium
High‐grade sarcoma diagnosis and prognosis: Biomarker discovery by mass spectrometry imaging
Author(s) -
Lou Sha,
Balluff Benjamin,
Graaff Marieke A.,
Cleven Arjen H.G.,
Briaire de Bruijn Inge,
Bovée Judith V.M.G.,
McDonnell Liam A.
Publication year - 2016
Publication title -
proteomics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.26
H-Index - 167
eISSN - 1615-9861
pISSN - 1615-9853
DOI - 10.1002/pmic.201500514
Subject(s) - leiomyosarcoma , osteosarcoma , sarcoma , undifferentiated pleomorphic sarcoma , biology , cancer research , biomarker , oncology , metastasis , cancer , medicine , pathology , bioinformatics , soft tissue sarcoma , biochemistry
The combination of high heterogeneity, both intratumoral and intertumoral, with their rarity has made diagnosis, prognosis of high‐grade sarcomas difficult. There is an urgent need for more objective molecular biomarkers, to differentiate between the many different subtypes, and to also provide new treatment targets. Mass spectrometry imaging (MSI) has amply demonstrated its ability to identify potential new markers for patient diagnosis, survival, metastasis and response to therapy in cancer research. In this study, we investigated the ability of MALDI‐MSI of proteins to distinguish between high‐grade osteosarcoma (OS), leiomyosarcoma (LMS), myxofibrosarcoma (MFS) and undifferentiated pleomorphic sarcoma (UPS) ( N total = 53). We also investigated if there are individual proteins or protein signatures that are statistically associated with patient survival. Twenty diagnostic protein signals were found characteristic for specific tumors ( p ≤ 0.05), amongst them acyl‐CoA‐binding protein ( m/z 11 162), macrophage migration inhibitory factor ( m/z 12 350), thioredoxin ( m/z 11 608) and galectin‐1 ( m/z 14 633) were assigned. Another nine protein signals were found to be associated with overall survival ( p ≤ 0.05), including proteasome activator complex subunit 1 ( m/z 9753), indicative for non‐OS patients with poor survival; and two histone H4 variants ( m/z 11 314 and 11 355), indicative of poor survival for LMS patients.